Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Other
    • ASN Publications
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • ASN Publications
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Visit ASN on Facebook
  • Follow CJASN on Twitter
  • CJASN RSS
  • Community Forum
Erratum
You have accessRestricted Access

Correction

CJASN November 2019, 14 (11) 1653-1654; DOI: https://doi.org/10.2215/CJN.09840819
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading
  • diuretics
  • pharmacology
  • edema
  • nephrotic syndrome
  • clinical

Ellison DH: Clinical Pharmacology in Diuretic Use. Clin J Am Soc Nephrol 14: 1248–1257, 2019; DOI: https://doi.org/10.2215/CJN.09630818.

Because of author error, the following corrections have been issued for this article:

  1. The label for “Absorption Varies” in Figure 2A should have referenced Table 2, not Table 1. The corrected Figure 2 is reprinted below.

  2. The authors have also reported the following typographical error on page 1251: “antinatriuresis” should have been “natriuresis.” The corrected word is in boldface font in situ in the paragraph below from the article.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

“There are additional reasons that CKD is a loop diuretic–resistant state. Metabolic acidosis, which is frequently observed in uremia, depolarizes the membrane potential of proximal tubule cells (37), which also decreases organic anion secretion, an effect that may explain why diuretic secretion is enhanced by alkalosis (38). In addition to a shift in the dose-response curve, patients with CKD and those taking NSAIDs have a downward shift of the ceiling natriuresis, when expressed as absolute sodium excretion (rather than fractional). The mechanism for resistance attributable to NSAIDs is complex. Loop diuretic inhibition of NaCl reabsorption at the macula densa stimulates both renin secretion and prostaglandin (PG) production, the latter predominantly via cyclooxygenase-2 (39). When this happens, PG E2 feeds back on tubules, contributing to the resulting natriuresis by inhibiting NaCl transport along the thick ascending limb and collecting duct (40,41). NSAIDs block this PG-mediated natriuresis. When used chronically, NSAIDs increase the abundance and activity of NKCC2 along the thick ascending limb (42). Additionally, loop diuretics inhibit the second transporter isoform, NKCC1, mentioned above, which is also expressed by vascular smooth muscle cells; loop diuretics contribute to afferent arteriolar vasodilation by blocking this transporter (43), thus helping to maintain GFR despite a lower ECF volume. Again, this compensatory adaptation is largely dependent on PG production and can be blocked by NSAIDs. The clinical consequence of these effects is evident in the association between recent use of NSAIDs and risk for hospitalization in patients with heart failure (34). In fact, the combination of three classes of drugs that affect hemodynamics of the kidney, loop diuretics, angiotensin-converting inhibitors (or receptor blockers), and NSAIDs, is associated with AKI (44).”

Footnotes

  • Published online ahead of print. Publication date available at www.cjasn.org.

  • Copyright © 2019 by the American Society of Nephrology
PreviousNext
Back to top

In this issue

Clinical Journal of the American Society of Nephrology: 14 (11)
Clinical Journal of the American Society of Nephrology
Vol. 14, Issue 11
November 07, 2019
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in CJASN.
Enter multiple addresses on separate lines or separate them with commas.
Correction
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Correction
CJASN Nov 2019, 14 (11) 1653-1654; DOI: 10.2215/CJN.09840819

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Correction
CJASN Nov 2019, 14 (11) 1653-1654; DOI: 10.2215/CJN.09840819
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Footnotes
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

  • Statement of Clarification: Chronic Kidney Disease from Polyvinylpyrrolidone Deposition in Persons with Intravenous Drug Use
  • Correction: Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults with ADPKD: A Randomized Controlled Trial
  • Correction: Prevention of Bloodstream Infections in Patients Undergoing Hemodialysis
Show more Erratum

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Related Articles

  • Clinical Pharmacology in Diuretic Use
  • PubMed
  • Google Scholar

Keywords

  • diuretics
  • Pharmacology
  • Edema
  • nephrotic syndrome
  • Clinical

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Trainee of the Year
  • Author Resources
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • CJASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About CJASN
  • CJASN Email Alerts
  • CJASN Key Impact Information
  • CJASN Podcasts
  • CJASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe to ASN Journals

© 2022 American Society of Nephrology

Print ISSN - 1555-9041 Online ISSN - 1555-905X

Powered by HighWire